| Purpose | (Clinical Focus: This value set targets testosterone medications administered through injection for use in masculinizing hormone therapy (MHT) for transgender men. It encompasses various injectable formulations and dosages of testosterone esters, including testosterone enanthate and testosterone cypionate.),(Data Element Scope: This value set applies to the category of medications used in MHT. It specifically captures parenteral testosterone delivered by injection, excluding other administration routes like gels or patches.),(Inclusion Criteria: The value set includes a comprehensive range of injectable testosterone products:
Testosterone enanthate in various concentrations (100mg/ml, 200mg/ml) and presentations (vials, prefilled syringes).
Testosterone cypionate in different concentrations (100mg/ml, 200mg/ml) and presentations (vials, prefilled syringes).
Brand and generic names are included for informational purposes (e.g., Andro LA, Delatestryl, Depotest, Xyosted).
Testosterone undecanoate (250mg/ml) is included although it is a less commonly used long-acting injectable form.
The value set captures auto-injector presentations of testosterone enanthate in various dosages (100mg/ml, 150mg/ml, 200mg/ml).),(Exclusion Criteria: This value set excludes testosterone delivered through other routes, such as gels or transdermal patches.
It does not include medications other than testosterone that may be used in MHT regimens, such as finasteride.
It excludes any specific information about injection techniques or frequencies, which are determined by healthcare providers.) |
FHIR